Search

Kura Oncology Inc

Cerrado

SectorSanidad

10.72 -1.38

Resumen

Variación precio

24h

Actual

Mínimo

10.72

Máximo

10.91

Métricas clave

By Trading Economics

Ingresos

5M

-68M

Ventas

2.6M

21M

BPA

-0.77

Margen de beneficios

-327.331

Empleados

260

EBITDA

7M

-66M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+145.92% upside

Dividendos

By Acuity

Próximas Ganancias

3 nov 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

158M

1B

Apertura anterior

12.1

Cierre anterior

10.72

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

102 / 339 Clasificación en Healthcare

Kura Oncology Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

24 sept 2026, 20:07 UTC

Kura Oncology Inc's shares fell sharply, pulling back from Wednesday's close and settling near the bottom of its one-month trading range.

23 sept 2026, 20:02 UTC

Correlated Moves

Kura Oncology Inc shares fell sharply, continuing a downward trend amid broader sector challenges and significant losses in the Direxion Daily S&P Biotech Bull 3X ETF.

22 sept 2026, 23:01 UTC

Kura Oncology Inc saw a modest rise in after-market trading, peaking shortly after the regular session ended, despite remaining below its 20-day moving average.

21 sept 2026, 19:25 UTC

Kura Oncology Inc shares fell sharply, currently trading below its 20-day moving average and near the lower end of its one-month range.

18 sept 2026, 20:06 UTC

Kura Oncology Inc is seeing a slight increase in trading, moving higher since Thursday's close but remaining near the lower end of its one-month range.

17 sept 2026, 20:08 UTC

Social Media

Kura Oncology Inc shares are advancing today, supported by increased retail commentary, despite pulling back from a session high earlier in the session.

16 sept 2026, 20:10 UTC

Kura Oncology Inc shares fell sharply after an early spike, closing significantly below its 20-day moving average and near the lower end of its one-month range.

15 sept 2026, 22:02 UTC

Kura Oncology Inc shares are higher in after-market trading, recovering from a low to a notable high during the session. No specific news was identified.

14 sept 2026, 20:13 UTC

Kura Oncology Inc shares are higher in after-market hours, though no specific news was identified. The price remains below its 20-day moving average.

10 sept 2026, 20:03 UTC

Social Media

Kura Oncology Inc shares are lower, continuing a three-day decline despite increasing sales and the approval of its menin inhibitor, KOMZIFTI.

9 sept 2026, 22:41 UTC

Kura Oncology Inc shares are rising in after-market trading, reflecting positive momentum in the biotechnology sector despite earlier session declines.

8 sept 2026, 20:02 UTC

News
Social Media

Kura Oncology Inc shares are lower today, influenced by declines in the Biotechnology sector despite the appointment of a new Chief Financial Officer.

3 sept 2026, 19:47 UTC

Kura Oncology Inc shares are lower today, with no specific news driving the decline. Earlier, the stock rebounded from a session high.

2 sept 2026, 22:01 UTC

Kura Oncology Inc shares are higher in after-market trading, reflecting strength amid weaker-than-expected job growth reported by ADP.

28 ago 2026, 20:08 UTC

Kura Oncology Inc shares are lower today, reflecting broader market trends and rising U.S. Treasury yields amid concerns over inflation and monetary policy.

27 ago 2026, 23:46 UTC

Kura Oncology Inc shares are higher in after-market hours, rebounding from earlier declines and staying above recent moving averages. No specific news was identified.

26 ago 2026, 23:41 UTC

Kura Oncology Inc shares are higher in after-market trading, supported by positive market sentiment despite no specific company news.

25 ago 2026, 23:06 UTC

News

Kura Oncology Inc. reached a new 52-week high after CEO Troy Wilson acquired 100,000 shares for approximately $1.24 million, reflecting strong market sentiment.

24 ago 2026, 23:31 UTC

News
Social Media

Kura Oncology shares are higher in after-market hours following CEO Troy Wilson's $1.2 million stock purchase, boosting his ownership to 1.214 million shares.

21 ago 2026, 22:56 UTC

Kura Oncology shares declined in after-market trading, continuing a downward trend since Friday's close, despite remaining above the 20-day moving average.

20 ago 2026, 23:16 UTC

Kura Oncology Inc shares are higher in after-market trading, despite no specific news to explain the move. The stock remains above its 20-day moving average.

19 ago 2026, 19:21 UTC

Social Media

Kura Oncology Inc shares are higher, supported by positive biotechnology sentiment and social media discussions about a recent swing position at $12.57.

18 ago 2026, 23:06 UTC

Kura Oncology shares are higher in after-market trading, aligning with broader market trends amid rising sovereign bond yields and inflation concerns.

17 ago 2026, 22:51 UTC

Social Media
News

Kura Oncology shares rose in after-market trading after CEO Troy Wilson's $1.11 million stock purchase and positive earnings report highlighting $9.1 million in revenue.

14 ago 2026, 22:01 UTC

Kura Oncology Inc shares are higher in after-market trading, recovering from an earlier decline. The stock remains above its 20-day moving average.

13 ago 2026, 23:52 UTC

Kura Oncology Inc is trading higher in after-market hours, reflecting broader market optimism following recent economic data and a stable producer price index.

12 ago 2026, 23:01 UTC

News
Social Media

Kura Oncology reported second-quarter revenue of $20.87 million, driven by a 57% increase in net product revenue for KOMZIFTI, shares higher in after-market hours.

10 ago 2026, 19:43 UTC

Event
News

Kura Oncology Inc shares rise as the company highlights ziftomenib's preclinical development in a *Blood* publication, enhancing its positioning in acute myeloid leukemia treatment.

7 ago 2026, 23:36 UTC

Kura Oncology Inc shares are lower in after-market hours, retracing from earlier gains. The stock remains below its 20-day moving average.

6 ago 2026, 21:02 UTC

Kura Oncology Inc shares are higher in after-market trading, reflecting a notable increase since Thursday's close amid positive sentiment in the broader market.

Comparación entre iguales

Cambio de precio

Kura Oncology Inc previsión

Precio Objetivo

By TipRanks

145.92% repunte

Estimación a 12 Meses

Media 26.461 USD  145.92%

Máximo 40 USD

Mínimo 12.15 USD

De acuerdo con 10 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Kura Oncology Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

10 ratings

10

Comprar

0

Mantener

0

Vender

Sentimiento

By Acuity

102 / 339 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Kura Oncology Inc

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; and strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies. The company was founded in 2014 and is headquartered in San Diego, California.